This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rowlinson-Busza, G. Articles by Epenetos, A. A. Search for Related Content PubMed PubMed Citation Articles by Rowlinson-Busza, G. Articles by Epenetos, A. A.

Uptake and Distribution of Specific and Control Monoclonal Antibodies in Subcutaneous Xenografts following Intratumor Injection

Imperial Cancer Research Fund Oncology Group, Department of Clinical Oncology [G. R-B., A. B., A. A. E.], and Histopathology Department [A. B., T. K.], Royal Postgraduate Medical School, Hammersmith Hospital, DuCane Road, London W12 OHS, England

Nude mice bearing s.c. xenografts of the human colon adenocarcinoma HT29 were given intratumor injections of a mixture of ¹²⁵I-labeled specific antibody (AUA1) and ¹³¹I-labeled control antibody (HMFG1), or with the labels reversed.

After dissection at 1 and 4 h postadministration, both specific and control antibodies had 47–63% of the injected dose (% ID) in the tumor. By 24 h, the tumor contained 43 ± 11% ID of AUA1 which persisted at around this level for 5 days and remained at nearly 20% ID at 18 days. In contrast, the HMFG1 activity was 23 ± 9% ID at 24 h, which continued to fall and was less than 5% ID by 7 days. Normal organ levels were less than 2% ID/g for both antibodies, with HMFG1 being higher than AUA1 at all times, resulting in specificity indices greater than 20 by 5 days.

Autoradiography of tumors removed 2 h postinjection of ¹²⁵I-labeled AUA1 or HMFG1 showed high levels of antibody at the injection site. At 48 h and 7 days postinjection, the specific antibody was bound to the surface of tumor cells in islands remote from the injection site, whereas the control antibody was found only in the stroma and blood vessels, or as diffuse nonspecific uptake.

These data indicate that intratumor injection of radiolabeled monoclonal antibodies may achieve high radiation doses in accessible tumors without systemic irradiation.

¹ To whom requests for reprints should be addressed.

² Financially supported by the Ministry of National Economy of Greece (Technical Assistance Department).

Received 11/14/90. Accepted 4/ 5/91.

This article has been cited by other articles:

				K. J. Harrington, G. Rowlinson-Busza, K. N. Syrigos, P. S. Uster, R. G. Vile, and J. S. W. Stewart Pegylated Liposomes Have Potential as Vehicles for Intratumoral and Subcutaneous Drug Delivery Clin. Cancer Res., June 1, 2000; 6(6): 2528 - 2537. [Abstract] [Full Text]

				C.-T. Kuan, C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner 125I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts Clin. Cancer Res., June 1, 1999; 5(6): 1539 - 1549. [Abstract] [Full Text] [PDF]